Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

RNS just out confirming confirming that coverage will be implemented on a national basis for reimbursement of the use of oesophageal Doppler monitoring to guide fluid therapy in ventilated patients in intensive care and for all patients undergoing surgery requiring fluid management.

Things are hotting nicely.

Out today the publication of the final decision memorandum by the US Centers for Medicare & Medicaid Services (CMS) confirming that coverage will be implemented on a national basis for reimbursement of the use of oesophageal Doppler monitoring to guide fluid therapy in ventilated patients in intensive care and for all patients undergoing surgery requiring fluid management.

Once the insurance is put in place then reimbursement to the physician for the
time and skill required to manage patients using ODM would be a matter of course. At shareclubuk.co.uk we view todays news as being most positive, establishing ODM as a standard of care in the USA. Opening up the worlds number one market for the company. Any comments please let the club know?

Looking at L2 the MM's are fighting to buy your shares, and not too keen to sell.
It appears to be working, with sales now catching up with Buys the PI,s are being tempted with a quick profit.
The institutions MUST be watching this share closely.
Would love to be able to see any buy orders in the background not showing on the order book.
(Thats probably jinxed it)

Excellent sp performance over the last week or so, the message is getting through at last, 50%+ profit atm, but imo fwiw, we are only just scratching the surface and this could be an exciting and much more profitable ride.
2517

Nice update re Reimbursement in the USA.
Things can now surely only go one way. UP.

Sp up and down like a yoyo at present. I put it down to profit taking.
For a change I increased my holding in a share at the perfect time.
Up over 20% in 2 weeks. No intention of selling yet.

greekman-----bound to get some profit taking but imo there is much more upside to come, and rather than try to be too clever by selling and re-buying I will sit on them and ride out the down days, I firmly believe that this is one for the future.
2517

Not seen this for a while.
All 7 Market Makers are showing same price as each other on the offer and ask.
Are they expecting something and just sitting on their hands waiting, not knowing which way to jump. Also the spread is a bit wider than usual, another sign of them not being sure which way it's heading.
Could always be a coincidence, but strange all the same.

Positive comment in shares today.
2517

RNS...Instiution selling.

It's never good when an institution sells.
They probably got tired of waiting for the CardioQ contracts to come flooding in.
Their clients were perhaps hoping to see profits increase faster.
Me, still being patient.

And me.
2517

Institution? Surely that's just MAN Financial who do spread bets. That's a load of spread betters closing their positions. That's nothing to worry about.

Me, I'm patient. The patient dog eats the fattest bone.

Hi Arf Dysg,

Could be as you say but Man Financial have been connected to Deltex for some time, and also deal in online futures, options, 'equities', forex, CFD's, free research and quotes.
.

Man Financial Limited first mentioned on 10/01/06 when they declared a holding of 2,360,000 putting them over the notifiable threshold.
They had 3,260,000 21/02/06 reduced to 3,135,000 on 22/02/06 so they must have bought another 900,000 sometime between the 2 dates.
The latest sale of 635,000 as stated puts them below the notifiable threshold, but still leaves them with a reasonable size holding.
So they look to have been in Deltex (with a notifiable holding) from 10/01/06.
If they held a lesser amount before that we have no way of knowing.

But like you patient, and not worried.

RNS out.

This placing will represent approximately 8.97 per cent. of the entire
issued share capital of the Company immediately following Admission.

'Deltex Medical has reached a key stage in its development where it is
experiencing both sustained and sustainable growth in all of its key markets.
Furthermore the Company's potential for future growth has been enhanced
significantly by the recent announcement of reimbursement coverage in the USA.
This investment in the expansion of our manufacturing capacity will allow us to
meet the rising demand for our products.'

Placings are sometimes for good reasons, sometimes bad. I will go with this placing being positive for the sole reason I believe some orders are in the pipeline and the extra funds are needed to speed up the manufacturing progress.

All IMHO of course.

THE COUNT--->ALL

Ooops, I wrongly posted this earlier on the traders thread thinking it was this one.

Post as follows....

THE COUNT--->ALL

The placing price is slightly disappointing, but then again, who llikes placings for any reason? I understand the company were hoping to do this at around the 25p mark but institutions originally wanted to do this at 20p and the company turned it down.

I wasn't aware of this until very recently, but the company, by this month, were running close to their capacity to produce probes. Obviously this signifies growth and it is a fact that all their territories have continued to grow. Given the setting of our market, you cannot fail to deliver on any orders as otherwise, it would be lethal to the company itself.

The bulk of the monies is to be used to fund a large expansion in the production capacity....I understand this to be up to a capacity of 20,000 probes per month from a present cpacity of 6,000 - 7,000 probes per month.

The company cannot raise any more money as this is their present limit without holding an EGM. I know its not a pleasant thing to do for existing shareholders, but it really was due to prohibitive costs that they didn't bring everybody in on the placing. The placing was done very quickly.

It's also the case that many investors regard all placings to be an evil force from the dark side. It is a necessary and important function of having a stockmarket ilsting and it is being done predominantly to fund the necessary expansion in our capacity.

The signs are all there...they are running close to capacity now and are expecting to reach their limit shortly....likely in the second half of the year. We sold about 39,000 probes throughout the whole of last year. If they reach their capacity of say 6,500 probes per month, that would annualise the probe sales at about 78,000 units. Now with the increased capacity, we will have the potential for about 240,000 units pa.

I don't like this as much as any of you, but it is necessary. For now I am biting the bullet.

Regards.

THE COUNT!

The Count,

Thanks re the extra detail.

Looks like the PI's liked it. On a bad day for the market Deltex are up.

Now will be nice to see, either new institutions buying, or/and existing ones increasing holdings.

Greek.

All, been in and out of DEMG three times, twice at frustrating losses triggered by stops and once re-couping them back with a well timed buy low, sell high.
Just wondered whether DEMG is now about to realise the potential but also thoughts on the competition Lidco? They reported strong sales this week but also received a patent in USA.

I have posted their RNS's below for your comments compared to DEMG?
I currently have no investment in either but DEMG has been on my watchlist for what seems to be forever.

LiDCO Group Plc
('the Company')

AGM Trading Update
Revenue Growth - Driven by Monitor Placements

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, will today
hold its Annual General Meeting at 11am. At the meeting Dr. Terry O'Brien,
Chief Executive of LiDCO, will provide the following update on trading:

"The Company stated in its preliminary results in April that it had already
seen a healthy increase in revenues. I am pleased to be able to report
encouraging results for the first four months of trading to the 31st of May
with sales up 61% over the equivalent period last year. Increased revenues have
been achieved in all territories - with particularly marked growth seen in
Europe. Sales have been driven by a shortening of the monitor sales cycle
during the period. The installed base is now standing at 1098 units
representing an increase of 189, 21%, over the last 12 months. Margins
(excluding our leasing arrangements) have been maintained and administration
expenses continue to be well controlled and within managements' budgets.

The Directors of the Company believe that the competitive activity remains
strong and that LiDCO remains on track to achieving expectations."

Notes for Editors

About LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery. The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London. For more information
please see
www.lidco.com
.

The Company's manufacturing facility is in Hoxton, London and its current
products are:

* LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
range of real-time, continuous hemodynamic parameters including cardiac output,
oxygen delivery and fluid volume;

* LiDCO disposables: used in conjunction with the LiDCOplus Monitor to
accurately determine cardiac output in a minimally-invasive manner.

* LiDCOview - software product for use on a PC: designed to aide clinical
audit, teaching and research activities.

* LiDCOlive - software product in development for the remote display of
hemodynamic monitoring parameters derived through use of the LiDCOplus monitor.

Distribution Network:

The Company has now achieved registration of its products in 14 markets in
Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and
USA, and elsewhere through a worldwide network of specialty critical care
distributors.

LiDCO Group Plc

('the Company')

Grant in the US of a Patent for Setting and Adjusting of a Cardiac
Biventricular Pacemaker

Supports Interventional Cardiology Opportunity

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, today
announces that it has received confirmation of the approval of its US Patent
application for a new method and apparatus for optimally adjusting a
biventricular pacemaker - used for the treatment of congestive heart failure
(CHF). The method involves the measurement of changes in certain hemodynamic
parameters (arterial pulse pressure and stroke volume) that have been shown to
reflect improvements in the heart's pumping action (ventricular performance).
Using the LiDCOplus Monitor these parameters are measured minimally invasively
and beat-to-beat.

Dr Terry O'Brien (Chief Executive of LiDCO) stated: "The use of our technology
today is predominantly for the treatment of intensive care and anesthesia
patients. However, we have always thought that the interest in using our
products within interventional cardiology would grow as the biventricular
pacemaker market developed. Accordingly, a number of influential university
hospitals are field trialing the use of our technology with a view to improving
the response of patients being treated for CHF with implantable biventricular
pacemakers. Although this is still somewhat early days, the grant of additional
intellectual property in this arena means that if the results of these trials
prove positive, we should have a strong and protectable market position."

Background to CHF, the patent and its usefulness in CRT/biventricular pacing:

Progressive congestive heart failure (CHF), is a growing problem among men and
women age 50-80 years. The condition affects 2-4 million people in the United
States and nearly 15 million people worldwide. The economic cost of heart
failure is estimated at $40 billion per year. Heart failure is a clinical
syndrome caused by a reduction in the heart's ability to pump blood around the
body. The heart's main chambers (the ventricles) should pump simultaneously and
in synchrony with the heart's upper chambers (the atria). If the wave of
contraction lacks synchrony the heart becomes less efficient as a pump and
starts to deteriorate. The problem underlying heart failure is one of delay in
the electrical activation of the left ventricle. This causes inefficient
pumping of blood to the body. The patient experiences a range of symptoms
including shortness of breath, swelling in the ankles or legs, weight gain, and
fatigue (`heart failure').

Recent pharmaceutical-based therapeutic advances have resulted in decreased
mortality rates in patients with CHF. However, despite these advances the
overall long-term prognosis and quality of life are still limited in patients
with moderate to severe heart failure. Therefore, device-based therapeutic
approaches are also warranted. Cardiac resynchronization therapy (CRT), or
biventricular pacing, aims to restore synchronous cardiac contraction by
delivering electrical impulses to three of the four chambers of the heart - the
right atrium and both ventricles. The result is that both ventricles beat in
synchrony, thus improving the pumping action of the heart and reducing the
symptoms of heart failure. CRT devices are available for sale for the treatment
of heart failure and are manufactured and sold by some of the biggest
cardiovascular corporations including Medtronic, Guidant and St. Jude Medical.
A number of studies have indicated that implantation of these devices improves
the clinical symptoms of people with heart failure. The devices cost thousands
of pounds each and require a surgical procedure/operation to implant both the
device and the wires.

In order to reduce the symptoms of heart failure, CRT devices can adjust/reset
the electronic conduction delay times from the atrium to the ventricles, thus
reducing the lack of cardiac synchrony. In a significant number of cases this
approach does not improve the clinical symptoms of heart failure. This can be
because the patient's heart will not respond to this approach, but also because
the device has not been optimally set up and/or adjusted to improve the
patient's ventricular performance. LiDCO's patent outlines how the LiDCOplus
Monitor can be used in conjunction with the outlined method in order to improve
patient screening for biventricular pacing suitability, to improve the
electrical lead placement, and to optimize pacemaker settings in terms of
choosing the appropriate heart rate and various chamber delays.